The 4 Best Tech Stocks In 2021 Are Pioneers Of The New Economy

On the gaming side of the business, Microsoft is releasing its newest Xbox in November, and it recently acquired ZeniMax Media, the parent company to Bethesda Softworks, the creators of Doom, Fallout, and Elder Scrolls for $7.5 billion. Gaming has been huge this year with more people staying home, and Microsoft saw record engagement and monetization last quarter. That's a trend not likely to slow down with the launch of its new console.

While Microsoft has been around for quite a long time, being founded in 1975, they have really started to hit their stride. As companies around the world go digital, Microsoft is often the first choice, and with best in class products, it should find a place in any everyone's portfolio.

One the Best Tech Stocks in 2021 Is Saving Lives

2020 will go down in the history books, not for the Lakers winning the NBA championship, Rafael Nadal winning his 13th French Open, the wildfires in California, or even the UK leaving the European Union. 2020 will be the year of the pandemic. As of November, we have already passed 40 million global COVID-19 cases and 1 million deaths, making this one of the worst pandemics in modern history.

As the world continues to wait for a COVID-19 vaccine from one of the dozens of companies developing a cure, we have realized one thing: Faster drug development could save millions of lives.

And technology is essential to making it happen.

This is why I'm looking to the future with Schrodinger Inc. (NASDAQ: SDGR). Schrodinger has created one of the most advanced drug discovery platforms on the market. It's used by the world's largest pharmaceutical companies, which are also using it to develop drugs in house. In light of the pandemic, Schrodinger has grown its software revenue by 35% in the first half of 2020 vs. 2019 and has continued to move forward with the 12 programs that are in late-stage discovery.

Looking at usage between 2013 to 2019, we can see just how sticky its products are. Total annual contract value has grown from $32 million to $76 million, and it boasts a 96% customer retention rate with customers spending over $100,000.

With a broad pipeline of collaborative drug programs in discovery, phase 1, and phase 2, this company has a very bright future.

FinTech Stocks Top Our List

View single page >> |

Disclosure: None.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.